CompletedNot Applicable

Use of Faecal Calprotectin to Predict Enteropathy of the Preterm Neonates

France122 participantsStarted 2013-09-30

Plain-language summary

This study aims to evaluate a clinico-biological predictive score, associating the faecal calprotectin, for the diagnosis of enterocolitis and enteropathy of the preterm neonates.

Who can participate

Age range33 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Infants prematurely born at a gestational age of 33 weeks or less (or before the 7th month of pregnancy). * Patient whose parents or holders of parental authority signed an informed consent. Exclusion Criteria: * Patient with a malformation. * Lack of signature of the consent by parents or holders of parental authority.

What they're measuring

fecal calprotectin level

Timeframe: From birth to hospital discharge (3 months maximum).

Trial details

NCT IDNCT02010268

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-02-22

View on ClinicalTrials.gov More Enteropathy, Necrotizing Enterocolitis trials